New study into leukemia offers clearer understanding of its biology

January 27, 2017 by Nik Papageorgiou, Ecole Polytechnique Federale de Lausanne
New study into leukemia offers clearer understanding of its biology
Blast cells in leukemia. Credit: iStock Photos

Leukemia affects 350,000 people worldwide. It is a cancer of the white blood cells, which are the cells of the immune system and are produced by stem cells in the bone marrow. There are two types of chronic and two types of acute leukemia. One chronic type, chronic myeloid leukemia accounts for ~20% of all cases, and is caused by a mutated enzyme with unregulated activity. This enzyme comes in two sizes, the second of which is associated with acute lymphocytic leukemia. Being the focus of current leukemia treatment, understanding the role of the enzyme is critical. EPFL scientists have now used proteomics to compare the two forms of the enzyme extensively, uncovering a much clearer view of how it may give different forms of leukemia. The work, published in Leukemia, opens up possibilities for improved drug development and therapy.

Chronic myeloid leukemia is caused when two chromosomes in bone marrow swap specific parts. The resulting chromosome is called "Philadelphia", and now contains a fused gene that produces an abnormal enzyme called Bcr-Abl.

This enzyme, which is constantly on, comes into two different sizes, or isoforms: the bigger (p210) is associated with , while the shorter one (p190) is linked with , a fast-developing form that is very difficult to treat leading to death of patients within a few months. The data on the differences of the two Bcr-Abl isoforms is inconsistent and confusing, meaning that we need more clarity as to its role in the development of this type of cancer.

The lab of Oliver Hantschel at EPFL, in close collaboration with the Proteomics Core Facility at the School of Life Sciences, used a proteomics approach to study the two isoforms of Bcr-Abl. Proteomics is a cutting-edge field that uses mass spectrometry analysis, which enables to map the entire set of proteins of an organism, termed the proteome.

New study into leukemia offers clearer understanding of its biology
Scheme depicting the different signaling networks of the two Bcr-Abl isoforms determined in this study. Credit: Sina Maren Reckel/EPFL

The researchers looked at two factors: First, all of the ways each Bcr-Abl isoform interacts with other molecules in the cell, or its "interactome". This allowed them to map out how the two isoforms work with other molecules.

Second, the team looked at the isoforms' phosphoproteomics. This refers to a modification—phosphorylation— that many proteins, including Bcr-Abl undergo in the cell, whereby they are "turned on" with the addition of a phosphate group. Using mass spectrometry, the researchers were able identify and compare hundreds of phosphorylated proteins in .

By comparing the two, the researchers were able to map out that there are "surprisingly large" differences between the interactome and phosphoproteome of the two isoforms, even though they are both "turned on" in much the same way. These differences in interactions and activation could be related to how each isoform drives an entirely different form of leukemia, and opens up possibilities for targeting Bcr-Abl in more efficient and effective ways to treat the disease.

Explore further: Scientists propose solution for blast cells' classification in diagnostics of acute lymphoblastic leukemia

More information: S Reckel et al. Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics, Leukemia (2017). DOI: 10.1038/leu.2017.36

Related Stories

Scientists propose solution for blast cells' classification in diagnostics of acute lymphoblastic leukemia

September 19, 2016
Currently, diagnostics of acute leukemia are based on manual calculations of different types of cells by blood smears and bone marrow aspirations. The data from morphological research conducted by doctors in the microscopic ...

A new approach to fighting chronic myeloid leukemia

November 17, 2014
Chronic myeloid leukemia develops when a gene mutates and causes an enzyme to become hyperactive, causing blood-forming stem cells in the bone marrow to grow rapidly into abnormal cells. The enzyme, Abl-kinase, is a member ...

Study determines efficacy of two drugs to treat a form of leukemia

October 24, 2016
Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.

Researchers pinpoint potential enzyme for T-cell leukemia treatment

February 22, 2016
For the first time, researchers at Boston University have shown that T-cell leukemia cells use a particular cycle, called the TCA or Kreb cycle, to support their growth and survival.

Technique identifies chemotherapy-resistant cells within acute myeloid leukemia tumors

September 6, 2016
Although chemotherapy can sometimes cure acute myeloid leukemia and other hematologic cancers, many patients experience relapses when their tumors become resistant to available chemotherapies. This resistance may be caused ...

FDA approves Pfizer drug for rare blood cancer

September 4, 2012
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.

Recommended for you

Pancreatic cancer's addiction could be its end

November 13, 2018
Cancer cells are often described as cells "gone bad" or "renegade." New research reveals that in some of the deadliest cases of pancreatic cancer, these rebellious cells have an unexpected addiction. Now, scientists are investigating ...

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

Study finds promising therapeutic target for aggressive type of breast cancer

November 13, 2018
A new Nature Communications study led by University of Kentucky Markey Cancer Center researchers suggests that an enzyme known as Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) is a potential therapeutic target for triple negative ...

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Obesity both feeds tumors and helps immunotherapy kill cancer

November 12, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.